Sermorelin Reconstitution Calculator

Sermorelin acetate (GRF 1-29) is a synthetic, amidated 29-amino-acid analogue of the amino-terminal (N-terminal) segment of native human growth hormone-releasing hormone (GHRH). It received US approval for childhood growth failure (1997) and shows benefit in children with growth hormone deficiency (GHD). Its labeled action is direct stimulation of the pituitary to release growth hormone, raising plasma GH. Adult wellness, body-composition, and performance uses are off-label (a gap between clinical evidence and self-administration practice).

Pituitary GHRH-receptor activation raises GH, driving downstream IGF-1 production. In HIV-associated wasting, sermorelin was reported to increase IGF-1 and improve body composition (moderate evidence, not RCT). Across GHRH/GHS-class agents, improved body composition and reduced fat gain are described in hypogonadal males, though robust efficacy data are sparse. In healthy adults, performance or recomposition benefits remain unproven.

Injectable, subcutaneous (SC). A six-month pediatric study used SC GRF 1-29, and human pharmacokinetic work employed SC administration to a healthy volunteer; no oral formulation exists, and the peptide length precludes meaningful enteral absorption (mechanistic). Storage matters: sermorelin and its metabolite degrade rapidly at temperatures above 4°C and at pH below 7. Reconstitute with a near-neutral diluent, refrigerate after mixing, and keep cold while traveling (practitioner consensus).

No established adult dose. Community protocols commonly start at 100-200 mcg SC once nightly and titrate to 200-300 mcg; anti-aging practice ranges up to 100-500 mcg/day, single or split (community protocol). Bedtime dosing aims to approximate the natural nocturnal GH surge (community protocol). Unregulated product supply adds uncertainty: composition, dose, and stacking practices in gray-market chains are unreliable.

Structured pediatric treatment ran 6 months SC; long-term use in healthy adults is unstudied. Community practice favors 3–6 month blocks with breaks (community protocol). Cumulative GH-axis stimulation carries unproven but plausible risk: a case report linked ~20 years of cyclical sermorelin/GHRP-6 plus somatropin use in a bodybuilder to a symptomatic C3-C4 anterior cervical osteophyte with esophageal compression and dysphagia, though causation is hypothetical (case report).

Class-reported adverse effects for GHRH/GHS agents include fluid retention, myalgia/arthralgia, injection-site reactions, appetite changes, dysglycemia, and prolactin/cortisol elevations; frequencies are poorly quantified and largely not sermorelin-specific. Pregnancy and breastfeeding: no studies exist, and endocrine perturbation risk cannot be excluded (avoid (practitioner consensus)). High-dose, long-term safety in healthy adults is unknown.

Sermorelin is short-acting; daily (usually nightly) dosing is needed to mimic pulsatile GH release [1, 2]. CJC-1295 without DAC (Drug Affinity Complex) is a modified GHRH analogue; with DAC it binds albumin, extending half-life to allow less frequent dosing [2, 9]. Detection chemistry treats sermorelin, tesamorelin, and CJC-1295 (with and without DAC) as distinct analytes with shared metabolite biology, including the sermorelin (3-29)-NH2 metabolite. Practitioners choose sermorelin for daily pulsatile stimulation versus DAC conjugates for dosing convenience at the cost of sustained, non-physiologic GHRH exposure (practitioner consensus).

Yes, where tested. GHRH analogues are prohibited by the World Anti-Doping Agency (WADA) [7, 9]. Current assays detect sermorelin and its (3-29) metabolite in urine at 5–25 pg/mL and in plasma below 50 pg/mL, with intact drug detectable at least 4 hours post-dose (and longer in practice). Standard workplace drug screens do not include peptides, but WADA-accredited sport labs can identify recent use; do not assume clearance (practitioner consensus).